Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period.

Myriad Genetics spun off its therapeutics business in July 2009 to focus on molecular diagnostics going forward. Although the molecular diagnostics business is performing well, we remain concerned about the slowdown in revenue growth in recent quarters.

The competition confronting Myriad Genetics products in the biotechnology and genetics testing field is also a concern. We have an Underperform rating on the stock.

Zacks Investment Research

1. (MYGN) Myriad Genetics Inc Misses Forecasts by a PennyMyriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny...
2. (MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents EstimateYesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from...
3. (MYGN) Biotech Industry – Zacks Analyst InterviewsOVERVIEW The Biotech industry as a whole continues to underperform the market so far this...
4. (MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank BuyMyriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on...
5. (MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basisMyriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts...
6. (MYGN) Myriad Genetics – Revenue increased 53% from last yearMyriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great...

Search Posts by Tag: MYGN | Myriad Genetics Inc. | Diagnostic Substances | Healthcare

RSS Feeds by Tag: MYGN | Myriad Genetics Inc. | Diagnostic Substances | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author